Background: The aim of this study was to evaluate the short-term efficacy and safety of camrelizumab in combination with apatinib in the treatment of refractory or metastatic esophageal squamous cell carcinoma (ESCC).
Methods: We retrospectively reviewed the medical records of 30 patients with refractory or metastatic ESCC treated with camrelizumab in combination with apatinib at a single institution. The short-term efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors criteria. The safety was evaluated by the Common Terminology Criteria for Adverse Events criteria.
Results: Among all the 30 patients, the overall response rate and disease control rate were 8/30 (27%) and 19/30 (63%), respectively. Complete response was achieved in 0/30 (0%), partial response in 8/30 (27%), stable disease in 11/30 (36%), and progressive disease in 11/30 (37%). The median progression-free survival was 3.7 (95% confidence interval: 2.48 - 3.88) months and the median overall survival was not reached.
Conclusion: Our study has shown that camrelizumab in combination with apatinib is a promising therapy for patients with refractory or metastatic ESCC. This combination has a high response rate and favorable clinical safety.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/ijc.IJC_1275_20 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Endoscopic Vacuum Therapy for the Treatment of Atrial Fibrillation Ablation-Induced Esophageal Perforation.
ACG Case Rep J
March 2025
Department of Medicine, Division of Gastroenterology & Hepatology, Barnes-Jewish Hospital/Washington University in St. Louis, St. Louis, MO.
Esophageal thermal injury from atrial fibrillation ablation is not uncommon; however, full-thickness perforation is rare. Such injuries are often treated with surgical revision, stent placement, or medical management. Endoscopic vacuum therapy is a novel and emerging technique to repair transmural gastrointestinal defects; however, its use in the management of esophageal thermal ulceration and perforation after a cardiac ablation procedure is limited.
View Article and Find Full Text PDFEffectiveness and Toxicity of Cemiplimab Therapy for Advanced Cutaneous Squamous Cell Skin Cancer in a Community Oncology Practice.
Cancers (Basel)
February 2025
Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89148, USA.
Background: The immune checkpoint inhibitor cemiplimab has significant clinical activity in unresectable and metastatic cutaneous squamous cell carcinomas. There are limited real-world data available to assess the outcome of cemiplimab treatment in patients in a community practice setting.
Methods: We conducted a retrospective analysis of treatment outcomes following cemiplimab treatment (350 mg IV every 3 weeks) of squamous cell skin cancer.
[Merkel cell carcinoma: An update].
Bull Cancer
March 2025
Dermatologie, CHU de Tours, Tours, France; Réseau CARADERM, France.
Merkel cell carcinoma (MCC) is a rare skin cancer that mainly affects the elderly, and whose incidence is increasing. Although the exact origin of this cancer remains uncertain, research in recent years has revealed that MCC develops through two oncogenesis pathways: virally induced by the Merkel polyomavirus (80% of cases) and induced by mutations linked to ultraviolet rays (20% of cases). MCC is an aggressive cancer, with a high mortality rate and limited therapeutic options in advanced stage.
View Article and Find Full Text PDFFrequency of Culture-proven Bacterial Infection and Radiographic Pneumonia in Pediatric Heart Transplant Recipients.
Pediatr Infect Dis J
March 2025
Divisions of Pediatric Emergency Medicine and Pediatric Infectious Diseases, Baylor College of Medicine, Houston, Texas.
Background: Infection is a leading cause of death after pediatric heart transplants (PHTs). Understanding of common pathogens is needed to guide testing strategies and empiric antibiotic use.
Methods: We conducted a 3-center retrospective study of PHT recipients ≤18 years old presenting to cardiology clinics or emergency departments (EDs) from 2010 to 2018 for evaluation of suspected infections within 2 years of transplant.
Pharmacological aspects of FDA-approved novel drug therapies against cancer in 2023: a comprehensive review.
Naunyn Schmiedebergs Arch Pharmacol
March 2025
Department of Pharmacy, Panipat Institute of Engineering and Technology (PIET), Samalkha, Panipat, 132102, Haryana, India.
This manuscript is aimed at preparing a scientific report on anticancer drugs, covering pharmacological aspects, approved by the FDA in the year 2023. This article is anticipated to serve as a handy document of interest for oncologists, patients as well as academicians. The manuscript was prepared by studying the pre-clinical and clinical data available in the public domain specifically on the website of the USFDA, Clinical Trials, National Library of Medicine, and other sources.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!